EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metformin Suppresses Glioblastoma Tumor Growth and Progression Through the AMPK/FoxO3a/Survivin Axis

Fabiola Cavaliere, Michele Pellegrino, Alessandro Cormace, Sofia Spadafora, Mariarosa Fava, Seung Ho Yang iD, Jung Eun Lee, Marta Claudia Nocito, Rosa Sirianni iD, Ivan Casaburi, Cecilia Garofalo iD, Diego Sisci iD und 2 weitere

Cells · 2026

DOI: 10.3390/cells15030310 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Fabiola Cavaliere und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. Hauptthemen laut MEDLINE: Metformin, Survivin, Forkhead Box Protein O3, Glioblastoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PRIN PNRR 2022-European Union's NextGenerationEU initiative under the Italian Ministry of University and Research as part of the PNRR - M4C2-I1.1, Next Generation EU-Italian NRRP, Mission 4, Component 2, Investment 1.5, call for the creation and strengthening of 'Innovation Ecosystems', building 'Territor…, The Korean ARPA-H Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GB) is one of the most aggressive malignant brain tumors. Due to the high invasiveness of this cancer, surgical removal is often not possible, and relapses after surgery are very common, making current treatments ineffective. Developing new therapies or treatment combinations remains a major challenge in managing GB. Metformin (MET), an anti-diabetic medication, has recently gained attention for its potential anticancer effects. To better understand how MET inhibits GB growth at the molecular level, we studied its impact on survivin, a member of the inhibitor of apoptosis (IAP) family that is essential for GB cell survival, resistance to radio- and chemotherapy, and tumor recurrence. Using T98G and U87-MG cell lines, we performed cell viability, migration, and invasion assays, along with Western blot analysis, ChIP assays, and gene silencing experiments to examine key signaling pathways. We found that MET effectively inhibits the growth, viability, and invasiveness of GB cell lines through a molecular mechanism involving activation of the AMPK/FoxO3a/survivin pathway. In vivo studies support these findings, showing increased FoxO3a and decreased survivin in brain tissue sections from metformin-treated mice compared with untreated controls. These results suggest new possibilities for repurposing MET as an adjuvant treatment for GB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminSurvivinForkhead Box Protein O3GlioblastomaAMP-Activated Protein KinasesBrain NeoplasmsDisease ProgressionHumansAnimalsCell Line, TumorCell ProliferationSignal TransductionMiceCell MovementCell SurvivalMice, Nude

Stichwörter der Autor:innen

AMPKFoxO3aglioblastomametforminsurvivin

Substanzen

MetforminSurvivinForkhead Box Protein O3AMP-Activated Protein KinasesFOXO3 protein, humanBIRC5 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.
  • Department of Neurosurgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, 93 Jungbudaero, Paldal-gu, Suwon 16247, Republic of Korea.
  • IRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura 3, 40139 Bologna, Italy.

ORCID-Profile: Seung Ho Yang, Rosa Sirianni, Cecilia Garofalo, Diego Sisci, Catia Morelli

Förderung

  • PRIN PNRR 2022-European Union's NextGenerationEU initiative under the Italian Ministry of University and Research as part of the PNRR - M4C2-I1.1
  • Next Generation EU-Italian NRRP, Mission 4, Component 2, Investment 1.5, call for the creation and strengthening of 'Innovation Ecosystems', building 'Territor…
  • The Korean ARPA-H Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
  • PRIN PNRR 2022 Program of the European Union’s Next Generation EU initiative
  • Next Generation EU Italian NRRP
  • project Tech4You
  • Korean ARPA-H Project through the Korea Health Industry Development Institute
  • Ministry of Health & Welfare, Republic of Korea

Zitieren

APA

Cavaliere, F., Pellegrino, M., Cormace, A., Spadafora, S., Fava, M., Yang, S. H., Lee, J. E., Nocito, M. C., Sirianni, R., Casaburi, I., Garofalo, C., Sisci, D., Morelli, C., & Lanzino, M. (2026). Metformin Suppresses Glioblastoma Tumor Growth and Progression Through the AMPK/FoxO3a/Survivin Axis. Cells. https://doi.org/10.3390/cells15030310

Vancouver

Cavaliere F, Pellegrino M, Cormace A, Spadafora S, Fava M, Yang SH, et al. Metformin Suppresses Glioblastoma Tumor Growth and Progression Through the AMPK/FoxO3a/Survivin Axis. Cells. 2026. doi:10.3390/cells15030310

BibTeX
@article{Cavaliere2026,
  author = {Cavaliere, Fabiola and Pellegrino, Michele and Cormace, Alessandro and Spadafora, Sofia and Fava, Mariarosa and Yang, Seung Ho and Lee, Jung Eun and Nocito, Marta Claudia and Sirianni, Rosa and Casaburi, Ivan and Garofalo, Cecilia and Sisci, Diego and Morelli, Catia and Lanzino, Marilena},
  title = {Metformin Suppresses Glioblastoma Tumor Growth and Progression Through the AMPK/FoxO3a/Survivin Axis},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15030310}
}
Kostenlos starten →